Similar articles

• Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.

  Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP. Roland KL, et al. Vaccine. 2007 Dec 12;25(51):8574-84. doi: 10.1016/j.vaccine.2007.09.074. Epub 2007 Oct 26. Vaccine. 2007. PMID: 18045752
• Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks.

  Hamorsky KT, Kouokam JC, Bennett LJ, Baldauf KJ, Kajiura H, Fujiyama K, Matoba N. Hamorsky KT, et al. PLoS Negl Trop Dis. 2013;7(3):e2046. doi: 10.1371/journal.pntd.0002046. Epub 2013 Mar 7. PLoS Negl Trop Dis. 2013. PMID: 23505583 Free PMC article.
• [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].

  Carrada Bravo T. Carrada Bravo T. Rev Alerg. 1993 Jul-Aug;40(4):91-4. Rev Alerg. 1993. PMID: 8143024 Review. Spanish.
• Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.

  Kundu J, Mazumder R, Srivastava R, Srivastava BS. Kundu J, et al. FEMS Immunol Med Microbiol. 2009 Jul;56(2):179-84. doi: 10.1111/j.1574-695X.2009.00563.x. Epub 2009 May 5. FEMS Immunol Med Microbiol. 2009. PMID: 19453752
• Parameters for the rational design of genetic toxoid vaccines.

  Burnette WN. Burnette WN. Adv Exp Med Biol. 1996;397:61-7. doi: 10.1007/978-1-4899-1382-1_9. Adv Exp Med Biol. 1996. PMID: 8718583 Review. No abstract available.